

Gerit-Holger Schernthaner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6982706/publications.pdf>

Version: 2024-02-01

97
papers

3,481
citations

147566
31
h-index

143772
57
g-index

101
all docs

101
docs citations

101
times ranked

4817
citing authors

#	ARTICLE	IF	CITATIONS
1	Calcification Propensity in Serum and Cardiovascular Outcome in Peripheral Artery Disease. Thrombosis and Haemostasis, 2022, 122, 1040-1046.	1.8	4
2	Galectin-3 is linked to peripheral artery disease severity, and urinary excretion is associated with long-term mortality. Atherosclerosis, 2022, 341, 7-12.	0.4	1
3	Preclinical atherosclerosis and cardiovascular events: Do we have a consensus about the role of preclinical atherosclerosis in the prediction of cardiovascular events?. Atherosclerosis, 2022, 348, 25-35.	0.4	18
4	High-Density Lipoprotein Particle Subclasses in Statin-Treated Patients with Peripheral Artery Disease Predict Long-Term Survival. Thrombosis and Haemostasis, 2022, 122, 1804-1813.	1.8	1
5	GlycA for long-term outcome in T2DM secondary prevention. Diabetes Research and Clinical Practice, 2021, 171, 108583.	1.1	6
6	Evaluation of sCD163 and sTWEAK in patients with stable peripheral arterial disease and association with disease severity as well as long-term mortality. Atherosclerosis, 2021, 317, 41-46.	0.4	4
7	Vascular peroxidase 1 is independently associated with worse kidney function in patients with peripheral artery disease. Journal of Nephrology, 2021, 34, 165-172.	0.9	2
8	Soluble urokinase-type plasminogen activator receptor predicts peripheral artery disease severity and outcomes. Vascular Medicine, 2021, 26, 11-17.	0.8	0
9	Decrease of dipeptidyl peptidase 4 activity is associated with weight loss after bariatric surgery. Obesity Surgery, 2021, 31, 2545-2550.	1.1	3
10	Angiogeninâ€”A Proposed Biomarker for Cardiovascular Diseaseâ€”Is Not Associated With Long-Term Survival in Patients With Peripheral Artery Disease. Angiology, 2021, 72, 855-860.	0.8	2
11	The COVID-19 Pandemic and the Need for an Integrated and Equitable Approach: An International Expert Consensus Paper. Thrombosis and Haemostasis, 2021, 121, 992-1007.	1.8	21
12	Peripheral artery disease and depression: Prerequisites for a lose-lose situation?. Atherosclerosis, 2021, 329, 30-31.	0.4	0
13	Milestones in thromboangiitis obliterans: a position paper of the VAS-European independent foundation in angiology/vascular medicine. International Angiology, 2021, 40, 395-408.	0.4	8
14	Statin initiation in dialysis patients: The hardship of non-prescription. Atherosclerosis, 2021, 337, 53-56.	0.4	1
15	Thrombospondin-4 increases with the severity of peripheral arterial disease and is associated with diabetes. Heart and Vessels, 2020, 35, 52-58.	0.5	10
16	Finally, the big picture of morbidity and mortality in peripheral arterial disease?. Atherosclerosis, 2020, 293, 92-93.	0.4	4
17	The right place for metformin today. Diabetes Research and Clinical Practice, 2020, 159, 107946.	1.1	29
18	From the eye into the foot?. Atherosclerosis, 2020, 294, 41-43.	0.4	0

#	ARTICLE	IF	CITATIONS
19	The enigma to best screen, evaluate and diagnose peripheral artery disease. <i>Atherosclerosis</i> , 2020, 315, 79-80.	0.4	0
20	Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1597-1628.	1.8	131
21	New horizons for mortality risk stratification in PAD: Are targeted multiplex proteomics the next step?. <i>Atherosclerosis</i> , 2020, 311, 98-99.	0.4	0
22	Predictive power of novel and established obesity indices for outcome in PAD during a five-year follow-up. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 1179-1187.	1.1	13
23	Peripheral arterial disease and type 2 diabetes: Older patients still exhibit a survival benefit from glucose control. <i>Diabetes and Vascular Disease Research</i> , 2020, 17, 147916412091484.	0.9	3
24	The peripheral perfusion between two extremes: Is a fraction of the pulse wave enough information?. <i>Atherosclerosis</i> , 2020, 304, 53-54.	0.4	0
25	How many more data is required to give the kidney the attention it deserves? Time to act for the "Big Five" of cardiovascular risk. <i>Atherosclerosis</i> , 2020, 297, 146-148.	0.4	8
26	FP348SOLUBLE UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR (suPAR) IS ASSOCIATED WITH KDIGO CHRONIC KIDNEY DISEASE STAGE IN PATIENTS WITH PERIPHERAL ARTERIAL DISEASE. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, .	0.4	0
27	Frequency of Hypoglycaemia after Different Bariatric Surgical Procedures. <i>Obesity Facts</i> , 2019, 12, 397-406.	1.6	26
28	Albuminuria in Patients with Morbid Obesity and the Effect of Weight Loss Following Bariatric Surgery. <i>Obesity Surgery</i> , 2019, 29, 3581-3588.	1.1	6
29	Gestational diabetes and maternal obesity suggestively priming children's premature atherosclerosis: Is it the mother fault?. <i>Atherosclerosis</i> , 2019, 284, 214-215.	0.4	0
30	sCD40L: An overestimated marker for cardiovascular risk prediction?. <i>Atherosclerosis</i> , 2019, 291, 122-123.	0.4	0
31	Angiopietin-2 and Survival in Peripheral Artery Disease Patients. <i>Thrombosis and Haemostasis</i> , 2018, 47, 791-797.	1.8	7
32	Prevalence of Micronutrient Deficiency in Patients with Morbid Obesity Before Bariatric Surgery. <i>Obesity Surgery</i> , 2018, 28, 643-648.	1.1	63
33	FABP4 and Cardiovascular Events in Peripheral Arterial Disease. <i>Angiology</i> , 2018, 69, 424-430.	0.8	22
34	Chronic lung disorders and abdominal aortic aneurysms: An old clinical observation now proven?. <i>Atherosclerosis</i> , 2018, 268, 191-192.	0.4	0
35	Epidemiology of peripheral artery disease in Europe: VAS Educational Paper. <i>International Angiology</i> , 2018, 37, 327-334.	0.4	86
36	YKL-40 levels increase with declining ankle-brachial index and are associated with long-term cardiovascular mortality in peripheral arterial disease patients. <i>Atherosclerosis</i> , 2018, 274, 152-156.	0.4	8

#	ARTICLE	IF	CITATIONS
37	YKL-40: an innocent bystander or an active threat in acute and chronic cardiac diseases?. Polish Archives of Internal Medicine, 2018, 128, 636-637.	0.3	0
38	Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML. Leukemia Research, 2017, 59, 47-54.	0.4	58
39	Peripheral arterial disease and loss of physical function: Just two old friends?. Atherosclerosis, 2017, 257, 246-247.	0.4	2
40	Chronic kidney disease, mineral bone disease and future risk of peripheral artery disease: Do associations rule?. Atherosclerosis, 2017, 267, 153-155.	0.4	0
41	Peripheral arterial disease outcomes and association with suPAR: A bridge to myeloid precursors or mast cells or both?. Atherosclerosis, 2017, 264, 77-78.	0.4	0
42	Center-based patient care enhances survival of elderly patients suffering from peripheral arterial disease. Annals of Medicine, 2017, 49, 291-298.	1.5	26
43	EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus. Clinical Therapeutics, 2016, 38, 1288-1298.	1.1	28
44	Moderate alcohol consumption shifts to an atheroprotective phenotype: A glass of wine keeps atherosclerosis in check?. Atherosclerosis, 2016, 254, 305-306.	0.4	2
45	Do we need a new classification system for arteriosclerotic lesions in crural limb ischemia? Pros and Cons. Atherosclerosis, 2016, 251, 493-494.	0.4	1
46	YKL-40 and its complex association with metabolic syndrome, obesity, and cardiovascular disease. Anatolian Journal of Cardiology, 2016, 16, 959.	0.5	7
47	Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors. Blood, 2015, 125, 901-906.	0.6	239
48	Gender, metabolic control and carotid intima-media-thickness in children and adolescents with type 1 diabetes mellitus. Wiener Klinische Wochenschrift, 2015, 127, 116-123.	1.0	3
49	The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system. Diabetes and Vascular Disease Research, 2014, 11, 306-323.	0.9	55
50	Further Evaluation of Pro-Atherogenic and Anti-Angiogenic Effects of Nilotinib in Mice and in Patients with Ph-Chromosome+ CML. Blood, 2014, 124, 1800-1800.	0.6	5
51	Do We Still Need Pioglitazone for the Treatment of Type 2 Diabetes? A risk-benefit critique in 2013. Diabetes Care, 2013, 36, S155-S161.	4.3	86
52	Reduced adiponectin receptor signalling accelerates atherosclerosis and may worsen the outcome in type 2 diabetes mellitus – Another one of those missing links?. Atherosclerosis, 2013, 229, 30-31.	0.4	4
53	Research update for articles published in <sc>EJCI</sc> in 2011. European Journal of Clinical Investigation, 2013, 43, 1097-1110.	1.7	2
54	Endothelial Progenitor Cells Are Related to Glycemic Control in Children With Type 1 Diabetes Over Time. Diabetes Care, 2013, 36, 1647-1653.	4.3	49

#	ARTICLE	IF	CITATIONS
55	Diabetic nephropathy: new approaches for improving glycemic control and reducing risk. <i>Journal of Nephrology</i> , 2013, 26, 975-985.	0.9	28
56	YKL-40 is elevated in patients with peripheral arterial disease and diabetes or pre-diabetes. <i>Atherosclerosis</i> , 2012, 222, 557-563.	0.4	38
57	Thrombin generation in type 2 diabetes with albuminuria and macrovascular disease. <i>European Journal of Clinical Investigation</i> , 2012, 42, 470-477.	1.7	25
58	Circulating Angiopoietic Cells and Diabetic Retinopathy in Type 2 Diabetes Mellitus, with or without Macrovascular Disease. , 2011, 52, 4655.		31
59	Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. <i>American Journal of Hematology</i> , 2011, 86, 533-539.	2.0	254
60	Fetuin-A Levels Are Increased in Patients With Type 2 Diabetes and Peripheral Arterial Disease. <i>Diabetes Care</i> , 2011, 34, 156-161.	4.3	59
61	Cure of Type 2 Diabetes by Metabolic Surgery? A Critical Analysis of the Evidence in 2010. <i>Diabetes Care</i> , 2011, 34, S355-S360.	4.3	24
62	In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V. <i>Experimental Hematology</i> , 2010, 38, 744-755.	0.2	46
63	YKL-40 concentrations are not elevated in gestational diabetes. <i>European Journal of Clinical Investigation</i> , 2010, 40, 339-343.	1.7	15
64	Strict glycaemic control in diabetic patients with CKD or ESRD: beneficial or deadly?. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 2044-2047.	0.4	38
65	Elevated Fetuin-A Concentrations in Morbid Obesity Decrease after Dramatic Weight Loss. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 4877-4881.	1.8	97
66	Correlation of Different Circulating Endothelial Progenitor Cells to Stages of Diabetic Retinopathy: First In Vivo Data. , 2009, 50, 392.		79
67	Is the current therapeutic armamentarium in diabetes enough to control the epidemic and its consequences? What are the current shortcomings?. <i>Acta Diabetologica</i> , 2009, 46, 173-181.	1.2	22
68	Increase of Osteopontin Plasma Concentrations After Bariatric Surgery Independent from Inflammation and Insulin Resistance. <i>Obesity Surgery</i> , 2009, 19, 351-356.	1.1	28
69	Chrelin and Obestatin Levels in Severely Obese Women Before and After Weight Loss After Roux-en-Y Gastric Bypass Surgery. <i>Obesity Surgery</i> , 2009, 19, 29-35.	1.1	63
70	YKL-40 is Elevated in Morbidly Obese Patients and Declines After Weight Loss. <i>Obesity Surgery</i> , 2009, 19, 1557-1563.	1.1	69
71	Circulating levels of MCP-1 are increased in women with gestational diabetes. <i>Prenatal Diagnosis</i> , 2008, 28, 845-851.	1.1	34
72	Peptide YY and Glucagon-like Peptide-1 in Morbidly Obese Patients Before and After Surgically Induced Weight Loss. <i>Obesity Surgery</i> , 2007, 17, 1571-1577.	1.1	72

#	ARTICLE	IF	CITATIONS
73	Metformin â€œ from Devil to Angel. , 2007, , 77-86.		4
74	Hypertension and Diabetes. , 2007, , 417-436.		1
75	Expression of Cell Surface Antigens on Mast Cells: Mast Cell Phenotyping. , 2006, 315, 077-090.		16
76	Detection of molecular targets on the surface of CD34+/CD38âˆ’ stem cells in various myeloid malignancies. Leukemia and Lymphoma, 2006, 47, 207-222.	0.6	140
77	No effect of homocysteine-lowering therapy on vascular inflammation and haemostasis in peripheral arterial occlusive disease. European Journal of Clinical Investigation, 2006, 36, 333-339.	1.7	16
78	Soluble CD40L in patients with morbid obesity: significant reduction after bariatric surgery. European Journal of Clinical Investigation, 2006, 36, 395-401.	1.7	44
79	Effect of Massive Weight Loss induced by Bariatric Surgery on Serum Levels of Interleukin-18 and Monocyte-Chemoattractant-Protein-1 in Morbid Obesity. Obesity Surgery, 2006, 16, 709-715.	1.1	77
80	Relationship of Androgens to Insulin Resistance and Chronic Inflammation in Morbidly Obese Premenopausal Women: Studies before and after Vertical Banded Gastroplasty. Obesity Surgery, 2006, 16, 1214-1220.	1.1	27
81	Homocyst(e)ine-Lowering Therapy Does Not Affect Plasma Asymmetrical Dimethylarginine Concentrations in Patients with Peripheral Artery Disease. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 2175-2178.	1.8	30
82	Evaluation of normal and neoplastic human mast cells for expression of CD172a (SIRPÎ±), CD47, and SHP-1. Journal of Leukocyte Biology, 2005, 77, 984-992.	1.5	9
83	Insulin Resistance and Inflammation in the Early Phase of Type 2 Diabetes: Potential for Therapeutic Intervention. Scandinavian Journal of Clinical and Laboratory Investigation, 2005, 65, 30-40.	0.6	31
84	Overexpression of complement receptors and related antigens on the surface of bone marrow mast cells in patients with systemic mastocytosis. British Journal of Haematology, 2003, 120, 257-265.	1.2	44
85	Cerivastatin and atorvastatin inhibit IL-3-dependent differentiation and IgE-mediated histamine release in human basophils and downmodulate expression of the basophil-activation antigen CD203c/E-NPP3. Journal of Leukocyte Biology, 2003, 73, 107-117.	1.5	27
86	Detection of Novel CD Antigens on the Surface of Human Mast Cells and Basophils. International Archives of Allergy and Immunology, 2002, 127, 299-307.	0.9	76
87	Activation of Human Mast Cells through Stem Cell Factor Receptor (KIT) Is Associated with Expression of bcl-2. International Archives of Allergy and Immunology, 2002, 129, 228-236.	0.9	29
88	Stem Cell Factor-induced Bone Marrow Mast Cell Hyperplasia Mimicking Systemic Mastocytosis (SM): Histopathologic and Morphologic Evaluation with Special Reference to Recently Established SM-criteria. Leukemia and Lymphoma, 2002, 43, 575-582.	0.6	24
89	Recombinant allergens promote expression of CD203c on basophils in sensitized individuals. Journal of Allergy and Clinical Immunology, 2002, 110, 102-109.	1.5	156
90	Signal Transductionâ€”Associated and Cell Activationâ€”Linked Antigens Expressed in Human Mast Cells. International Journal of Hematology, 2002, 75, 357-362.	0.7	6

#	ARTICLE	IF	CITATIONS
91	A case of smouldering mastocytosis with peripheral blood eosinophilia and lymphadenopathy. <i>Leukemia Research</i> , 2002, 26, 601-606.	0.4	32
92	Expression of mast cell tryptase by myeloblasts in a group of patients with acute myeloid leukemia. <i>Blood</i> , 2001, 98, 2200-2209.	0.6	130
93	Expression, epitope analysis, and functional role of the LFA-2 antigen detectable on neoplastic mast cells. <i>Blood</i> , 2001, 98, 3784-3792.	0.6	48
94	Detection of tryptase in cytoplasmic granules of basophils in patients with chronic myeloid leukemia and other myeloid neoplasms. <i>Blood</i> , 2001, 98, 2580-2583.	0.6	58
95	A case of "smouldering" mastocytosis with high mast cell burden, monoclonal myeloid cells, and C-KIT mutation Asp-816-Val. <i>Leukemia Research</i> , 2001, 25, 627-634.	0.4	43
96	Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosis. <i>Leukemia Research</i> , 2001, 25, 529-536.	0.4	206
97	Utility of flow cytometric analysis of mast cells in the diagnosis and classification of adult mastocytosis. <i>Leukemia Research</i> , 2001, 25, 563-570.	0.4	124